Related references
Note: Only part of the references are listed.Impact of pathologic complete response on survival after neoadjuvant chemotherapy in early-stage breast cancer: a population-based analysis
Nathalie LeVasseur et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Efficacy of Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in ER-positive Breast Cancer: Results From a Prospective Institutional Database
Nathalie LeVasseur et al.
CLINICAL BREAST CANCER (2019)
Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor-Positive Early Breast Cancer: PALLET Trial
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer
P. Cottu et al.
ANNALS OF ONCOLOGY (2018)
Short-term outcomes of neoadjuvant hormonal therapy versus neoadjuvant chemotherapy in breast cancer: systematic review and meta-analysis of randomized controlled trials
Lei Huang et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2017)
Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis
Marta Bonotto et al.
BREAST (2017)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Neoadjuvant Endocrine Therapy for Estrogen Receptor-Positive Breast Cancer A Systematic Review and Meta-analysis
Laura M. Spring et al.
JAMA ONCOLOGY (2016)
Targeting the cyclin-dependent kinases (CDK) 4/6 in estrogen receptor-positive breast cancers
Richard S. Finn et al.
BREAST CANCER RESEARCH (2016)
Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration
V. Bossuyt et al.
ANNALS OF ONCOLOGY (2015)
Global Cancer Statistics, 2012
Lindsey A. Torre et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657)
Laura J. Esserman et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
Joel S. Parker et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Measurement of residual breast cancer burden to predict survival after Neoadjuvant chemotherapy
W. Fraser Symmans et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from national surgical adjuvant breast and bowel project protocol B-27
HD Bear et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
